Sterling Heights, MI, United States of America

Ken Barton

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ken Barton - Innovator in Cancer Therapy

Introduction

Ken Barton is a notable inventor based in Sterling Heights, MI (US). He has made significant contributions to the field of cancer therapy through his innovative research and development. His work focuses on utilizing novel adenoviruses to create effective treatments for cancer.

Latest Patents

Ken Barton holds a patent for "Methods and compositions for cancer therapy using a novel adenovirus." This invention comprises a unique virus that efficiently targets and kills mammalian cancer cells. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These agents are produced locally, aiding the virus in its mission to eliminate cancer cells while also sensitizing them to radiation. In preclinical studies, the virus has demonstrated effectiveness in killing various mammalian cancer cells, either alone or in combination with prodrug therapy and/or radiation therapy. This invention may provide a safe and effective treatment option for human cancer.

Career Highlights

Ken Barton is affiliated with the Henry Ford Health System, where he continues to advance his research in cancer therapy. His dedication to improving treatment options for cancer patients is evident in his innovative approach to utilizing adenoviruses.

Collaborations

Ken has collaborated with esteemed colleagues such as Svend O Freytag and Jae Ho Kim, contributing to the advancement of cancer treatment methodologies.

Conclusion

Ken Barton's innovative work in cancer therapy exemplifies the potential of novel approaches to treat complex diseases. His contributions may pave the way for safer and more effective cancer treatments in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…